This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Endo Pharmaceuticals Inc. FDA Accepts New Drug Application for Oxymorphone Extended Release And Immediate Release Formulations. Media Release: 19 Feb 2003. Available from URL: http://www.endo.com
Endo Pharmaceuticals Inc. Data from Studies Investigating Extended-Release Oxymorphone Presented Today at 10th World Congress on Pain. Media Release: 21 Aug 2002. Available from URL: http://www.endo.com
Endo Pharmaceuticals. Clinical Trial of New Opioid Product Shows Pain Reduction in Chronic Low Back Pain. Media Release: 20 Mar 2003. Available from URL: http://www.endo.com
Slatkin N, Frailey A, Ma T, et al. Oxymorphone extendedrelease offers long-term safety, effectiveness, and dose stabilization in cancer pain: results of a one-year interim report. Journal of Pain 4 (Suppl. 1): 84, Mar 2003
Kivitz A, Ma C, Ahdieh H. Oxymorphone extended-release improves pain and quality of life in patients with osteoarthritis: results of a randomized, double-blind, placebo-controlled, dose-ranging study. Journal of Pain 4 (Suppl. 1): 80, Mar 2003
Rights and permissions
About this article
Cite this article
Oxymorphone — Endo/Penwest. Drugs R&D 4, 204–206 (2003). https://doi.org/10.2165/00126839-200304030-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304030-00012